The cytomegalovirus gB/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread

Vaccination against human cytomegalovirus (CMV) infection remains high priority. A recombinant form of a protein essential for CMV entry, glycoprotein B (gB), demonstrated partial protection in a clinical trial (NCT00299260) when delivered with the MF59 adjuvant. Although the antibody titre against...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomes, A. C., Baraniak, I. A., Lankina, A., Moulder, Z., Holenya, P., Atkinson, C., Tang, G., Mahungu, T., Kern, F., Griffiths, P. D., Reeves, M. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950427/
https://www.ncbi.nlm.nih.gov/pubmed/36823200
http://dx.doi.org/10.1038/s41467-023-36683-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950427/
https://www.ncbi.nlm.nih.gov/pubmed/36823200
http://dx.doi.org/10.1038/s41467-023-36683-x

Ejemplares similares